Seismic Pharmaceuticals starts Phase 3 istaroxime trial in cardiogenic shock
Seismic Pharmaceuticals begins Phase 3 testing of istaroxime in cardiogenic shock, putting a 600-patient global trial at center stage.
Pharma & Biotech